U.S. Supreme Court rejects Amgen over cholesterol medication patent fight [Reuters]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Reuters
U.S. Supreme Court rejects Amgen over cholesterol medication patent fight WASHINGTON (Reuters) - The U.S. Supreme Court on Monday declined to take up Amgen Inc’s bid to reinstate a jury verdict it won against rivals Regeneron Pharmaceuticals Incand Sanofi SAin patent dispute over cholesterol medication. The justices turned away Amgen’s appeal of a 2017 decision by a lower court to set aside a jury’s verdict that two Amgen patents were valid and nullify a ban on sales of Regeneron and Sanofi SA’s cholesterol-lowering drug Praluent. Amgen had argued that the U.S. Court of Appeals for the Federal Circuit misunderstood the statutory requirements for patenting an invention. Reporting by Jan Wolfe and Lawrence Hurley; Editing by Will Dunham Our Standards: The Thomson Reuters Trust Principles.
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at TD Cowen from $370.00 to $360.00. They now have a "buy" rating on the stock.MarketBeat
- Can This High-Yield Dividend Stock Keep Beating the S&P 500? [Yahoo! Finance]Yahoo! Finance
- AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024 [Yahoo! Finance]Yahoo! Finance
- AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024PR Newswire
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- 4/10/24 - Form ARS
- AMGN's page on the SEC website